NervGen Pharma Corp. NGEN
1.35 USD +0.02 (+1.50%)
At closeNov 11, 2026, 4:00 PM EST
1.37 +0.02 +1.48%
After hours · Nov 11, 4:00 PM ET
1.33 Day range 1.39
1.28 52-week range 6.30
- YTD
- -75.89%
- 1 year
- -43.98%
News
defenseworld.net NervGen Pharma (NASDAQ:NGEN) Stock Has Consensus Price Target of $14.00 According to Brokerages NervGen Pharma (NASDAQ: NGEN - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six research firms that are currently covering the stock, Marketbeat Ratings reports.…
benzinga.com NervGen Doses First Participant In Phase 3 RESTORE Study Of NVG-291 For Chronic Cervical SCI; Enrollment Completion Expected In H2 2027, Topline Data In H1 2028 RESTORE is evaluating NVG-291’s potential to improve hand function and quality of life in individuals living with chronic cervical motor-incomplete spinal cord injuryStudy builds on functional…
seekingalpha.com NervGen Pharma: The Upside Is Large, But Phase 3 Decides Everything NervGen Pharma Corp. is executing the Phase 3 RESTORE trial for NVG-291, targeting functional recovery in chronic spinal cord injury. RESTORE is powered to detect a 2.5-point treatment effect, with…
seekingalpha.com NervGen Pharma Corp. (NGEN) Discusses Challenges and Advances in Drug and Therapy Trials for Spinal Cord Injury Transcript NervGen Pharma Corp. (NGEN) Discusses Challenges and Advances in Drug and Therapy Trials for Spinal Cord Injury Transcript
benzinga.com NervGen Announces It Will Restate Its Audited Annual Financial Statements For The Year Ended December 31, 2025, And Its Unaudited Interim Financial Statements For The Quarter Ended June 30, 2026 Adjustments have no impact on cash and cash equivalents, cash runway, or business operations.Restatement is expected to reduce previously reported stock-based compensation expense, warrant…
globenewswire.com NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments VANCOUVER, British Columbia, Sept. 25, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for…
globenewswire.com NervGen to Host Inaugural R&D Day on September 30, 2026 VANCOUVER, British Columbia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for…
globenewswire.com NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates VANCOUVER, British Columbia, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for…
benzinga.com Micron To Rally Around 87%? Here Are 10 Top Analyst Forecasts For Tuesday Summary: Wall Street analysts changed rating for JAZZ, AFRM, MNDY, NGEN, FCEL, RRR, ABNB, KARO. See how other analysts view these stocks.
benzinga.com HC Wainwright & Co. Maintains Buy on NervGen Pharma, Lowers Price Target to $15 HC Wainwright & Co. analyst Raghuram Selvaraju maintains NervGen Pharma (NASDAQ:NGEN) with a Buy and lowers the price target from $18 to $15.- benzinga.com Leerink Partners Initiates Coverage On NervGen Pharma with Outperform Rating, Announces Price Target of $10 Leerink Partners analyst Marc Goodman initiates coverage on NervGen Pharma (NASDAQ:NGEN) with a Outperform rating and announces Price Target of $10.
seekingalpha.com NervGen Pharma: I Think The Biggest Risks Are Now Behind It NervGen Pharma remains a Buy, with reduced regulatory, financing, and execution risks following FDA alignment on the Phase 3 RESTORE trial. NGEN's recent $60M capital raise secures funding for its…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com NervGen Pharma Increases Mixed Shelf Offering From $150M To $250M U.S.$250,000,000Common SharesDebt SecuritiesSubscription ReceiptsWarrantsUnitsThe amended and restated short form base shelf prospectus dated December 15, 2025 (the "Prospectus") of NervGen Pharma…
benzinga.com Why Is NervGen Pharma Stock Gaining Tuesday? NGEN stock climbs as NervGen Pharma NVG-291 hits a 100% responder rate in spinal cord injury gait analysis. Phase 3 set for mid-2026.
benzinga.com NervGen Pharma Announces Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery With NVG-291 In The Phase 1B/2a CONNECT SCI Study; Notes 100% Of Subjects Were Classified As Responders Against 10% For Placebo NVG-291 demonstrated statistically significant improvement in gait quality (p=0.0197), based on a Global Statistical Test integrating the established hallmarks of genuine neural recovery into a…
globenewswire.com NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com Crude Oil Edges Higher; US Consumer Sentiment Falls In May US stocks rose, Dow gained over 400 points. S&P 500 and NASDAQ also up. Health care shares jumped, while communication services fell. University of Michigan's consumer sentiment index hit record low.…
benzinga.com Dow Jumps 250 Points; BJ's Wholesale Shares Fall After Q1 Results US stocks rise with the Dow gaining 250 points. Health care shares jump while energy stocks fall. BJ's Wholesale Club stock falls 7% after earnings.
benzinga.com Why Estee Lauder Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket Estee Lauder (EL) shares jumped 11.8% in pre-market trading after ending discussions with Puig. Other gainers include PCLA, AKTX, LFS, BIYA, QTEX, GOVX, COHN, SQNS, and IMAX.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
globenewswire.com NervGen Announces Pricing of US$60.0 Million Public Offering of Securities VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session 
benzinga.com NervGen Pharma Announces Commencement Of Public Offering Of Common Shares The offering is being made pursuant to a prospectus supplement to an amended and restated short form base shelf prospectus dated December 15, 2025 (the "Base Shelf Prospectus") filed in all of the…
globenewswire.com NervGen Announces Proposed Public Offering of Securities VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class…
globenewswire.com NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates VANCOUVER, British Columbia, May 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class…
benzinga.com This LB Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed outlook on top names. See analyst rating changes, including upgrades/downgrades/initiations, on Benzinga.- benzinga.com HC Wainwright & Co. Initiates Coverage On NervGen Pharma with Buy Rating, Announces Price Target of $18 HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on NervGen Pharma (NASDAQ:NGEN) with a Buy rating and announces Price Target of $18.
- benzinga.com NervGen Pharma Appoints Keith Vendola CFO, Effective Immediately NervGen Pharma Corp. ("NervGen" or the "Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and…
globenewswire.com NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class…
globenewswire.com NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference VANCOUVER, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class…- benzinga.com NervGen Pharma Completes End-Of-Phase 2 Meeting With FDA, Restores Phase 3 Registrational Trial To Evaluate NVG-291 To Treat Chronic Tetraplegia NervGen Pharma Corp. ("NervGen" or the "Company") (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and…
globenewswire.com NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia VANCOUVER, British Columbia, April 07, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class…
globenewswire.com NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class…
seekingalpha.com NervGen Pharma: I See Promise, But The Clock Is Ticking (Rating Downgrade) NervGen Pharma Corp. demonstrates lasting functional improvements in chronic cervical spinal cord injury patients with NVG-291, supporting its unique regenerative approach. NGEN's regulatory…- benzinga.com NervGen Pharma Says In Connection With The Voluntary Delisting From TSXV, The Co. Has Terminated Its Previously Announced ATM Equity Program Launched On December 19, 2025 NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV:NGEN) (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury…
benzinga.com NervGen Pharma Voluntarily Delisting From TSX Venture Exchange, Effective March 16 NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury…
globenewswire.com NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange VANCOUVER, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing…
globenewswire.com NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing…
globenewswire.com NervGen Pharma to Participate at Upcoming Investor Conferences VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing…